The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy.
 
Roland Seiler
No Relationships to Disclose
 
Brian Winters
No Relationships to Disclose
 
James Douglas
No Relationships to Disclose
 
Bas W.G. van Rhijn
No Relationships to Disclose
 
Gottfrid Sjödahl
No Relationships to Disclose
 
Seth P. Lerner
Consulting or Advisory Role - Ferring; Nucleix; Oncogenex; Sitka; Taris BioMedical; Telesta Therapeutics; Urogen pharma; Vaxiion
Research Funding - Endo Pharmaceuticals; FKD Therapies; JenaValve; Roche/Genentech; Viventia Biotech
Travel, Accommodations, Expenses - BioCancell; Ferring; Oncogenex; Theracoat
 
Katherine A. Hoadley
No Relationships to Disclose
 
Scott A. North
Honoraria - Astellas Pharma; Janssen-Ortho; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Janssen Oncology; Merck; Novartis; Pfizer; Roche Canada; Sanofi
 
David James McConkey
Stock and Other Ownership Interests - Apocell
 
Woonyoung Choi
Patents, Royalties, Other Intellectual Property - MD Anderson Cancer Center
 
William Y. Kim
Stock and Other Ownership Interests - Agios; Bristol-Myers Squibb; Johnson & Johnson; Medivation; Merck
Patents, Royalties, Other Intellectual Property - BASE47 bladder cancer subtype classifier
 
Kim E.M van Kessel
Research Funding - MDxHealth
Travel, Accommodations, Expenses - MDxHealth
 
George N. Thalmann
No Relationships to Disclose
 
Elai Davicioni
Employment - GenomeDx
Leadership - GenomeDx
Stock and Other Ownership Interests - GenomeDx
Patents, Royalties, Other Intellectual Property - CANCER DIAGNOSTICS USING BIOMARKERS 20140066323
Travel, Accommodations, Expenses - GenomeDx
 
Simon J. Crabb
Honoraria - Astellas Pharma; Bayer
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen; Pfizer; Sanofi
Research Funding - Astex Pharmaceuticals; AstraZeneca
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen; Novartis; Sanofi
 
Joost L Boormans
Consulting or Advisory Role - Janssen
Speakers' Bureau - GlaxoSmithKline
 
Marc Dall'Era
Consulting or Advisory Role - Bayer; Janssen
Speakers' Bureau - Genomic Health; MDxHealth
 
Jonathan Lawrence Wright
No Relationships to Disclose
 
Michiel Simon Van Der Heijden
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Roche/Genentech (Inst)
Research Funding - Astellas Pharma (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis
 
Peter C. Black
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bayer; BioCancell; Biosyent; Cubist; Ferring; Janssen Oncology; Lilly; Merck; Novartis; Roche Canada; Sanofi; Sitka; Spectrum Pharmaceuticals
Speakers' Bureau - Ferring; Red Leaf Medical
Research Funding - iProgen; New B Innovation
Patents, Royalties, Other Intellectual Property - 1. PCT/CA2014/000787. Canada. 2014-11-03 Cancer Biomarkers and Classifiers and uses thereof. 2. #61899648 United States. 2013-03-13 Bladder cancer signature.
Travel, Accommodations, Expenses - Bayer; Janssen; Sanofi